Evidence map›Paper›PMID 40614970›Full record

ArticleMucosal immunology2025

Tofacitinib ameliorates Campylobacter-induced intestinal pathology by suppressing IFNγ producing ILCs and T cells.

Anna A Korchagina, Sergey A Shein, Wayne T Muraoka, Justin Nguyen, Qiangxing Chen, Anna A Tumanova, Austin W Todd, Carlos E Rivera, Rita Tamayo, Paolo Casali and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna A KorchaginaDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Sergey A SheinDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Wayne T MuraokaDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Justin NguyenDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Qiangxing ChenDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA; Department of Gastroenterology, The Second Xiangya Hospital, and Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China.
Anna A TumanovaDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Austin W ToddDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Carlos E RiveraDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Rita TamayoDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Paolo CasaliDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Ekaterina KorolevaDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA.
Alexei V TumanovDepartment of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229, USA. Electronic address: tumanov@uthscsa.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Intrinsic B cell epigenetic regulation of antibody and autoantibody responses by Sirt1R01AI105813 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CASALI, PAOLO · 2014 to 2023
$4.5M
Epigenetics of the autoantibody response in systemic lupusR01AI167416 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CASALI, PAOLO · 2021 to 2025
$3.6M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM145432 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jose E Cavazos, Ratna K Vadlamudi · 2023 to 2026
$2.3M
South Texas Medical Scientist Training Program (STX-MSTP)T32GM113896 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CAVAZOS, JOSE E · 2018 to 2022
$1.1M
FACSAria Fusion cell sorter for Flow Cytometry Shared ResourceS10OD030432 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BERTON, MICHAEL T · 2022 to 2022
$596k
Novel animal models to study organ-specific SARS-CoV-2-induced pathologyR21AI173816 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, MARTINEZ-SOBRIDO, LUIS · 2023 to 2024
$499k
Innate lymphoid cells in Campylobacter-induced colitisR21AI135574 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI TUMANOV, ALEXEI V · 2018 to 2019
$419k
Targeting SARS-CoV-2 induced lung immunopathology using novel genetic mouse modelsR21AI161400 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOROLEVA, EKATERINA, TUMANOV, ALEXEI V · 2022 to 2023
$419k
Epigenetic downregulation of the antibody response and inhibition of autoimmunityR56AI105813 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI CASALI, PAOLO · 2013 to 2013
$286k
NCI NIH HHS P30 CA054174NIAID NIH HHS R01 AI105813NIAID NIH HHS R01 AI167416NIAID NIH HHS R21 AI135574NIAID NIH HHS R21 AI161400NIAID NIH HHS R21 AI173816NIAID NIH HHS R56 AI105813NIGMS NIH HHS T32 GM113896NIGMS NIH HHS T32 GM145432NIH HHS S10 OD030432
6 · The paper itself

Abstract

Patients with autoimmune diseases are more susceptible to foodborne infections, which can be exacerbated by immunosuppressive therapy. Tofacitinib, a JAK/STAT pathway inhibitor, was recently approved for the treatment of ulcerative colitis, yet its effects on the pathogenesis of intestinal infections remain unclear. Here, we examined the impact of oral tofacitinib treatment in a mouse model of Campylobacter jejuni (C. jejuni) infection. Our results show that early tofacitinib administration attenuates intestinal pathology without affecting bacterial colonization. Specifically, tofacitinib suppressed CXCL1, CXCL2, CCL2 chemokine expression by intestinal epithelial cells, limiting recruitment of monocytes and neutrophils to the gut. In addition, JAK/STAT inhibition reduced IFNγ-producing innate lymphoid cells (ILCs) and T cells in the gut. Furthermore, tofacitinib suppressed IFNγ production and ameliorated intestinal disease in humanized mice. Cell-fate mapping revealed that tofacitinib predominantly inhibited IFNγ production by NK1.1

Indexed as

Campylobacter InfectionsCampylobacter jejuniInterferon-gammaIntestinesLymphocytesPiperidinesProtein Kinase InhibitorsPyrimidinesT-LymphocytesAnimalsDisease Models, AnimalHumansImmunity, InnateIntestinal MucosaMiceMice, Inbred C57BLInterferon-gammaPiperidinesProtein Kinase InhibitorsPyrimidinestofacitinibCampylobacter jejuniInfectious colitisInnate lymphoid cellsJAK/STATTofacitinib

Identifiers

PMID40614970
PMCPMC12431686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.